Overview

Hepatic Impairment Trial of Obeticholic Acid

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

This is a phase 1 study to evaluate the safety of a single 10 mg dose of obeticholic acid (OCA) in healthy volunteers and patients with liver disease.

Phase:

Phase 1

Details

Lead Sponsor:

Intercept Pharmaceuticals

Treatments:

Chenodeoxycholic Acid